Filtered By:
Source: Thrombosis Research
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 221 results found since Jan 2013.
Safety of venous thromboembolism prophylaxis with fondaparinux in ischemic stroke
We examined adverse event frequency in hospitalized patients with ischemic stroke who received VTE prophylaxis with fondaparinux versus UFH.
Source: Thrombosis Research - December 13, 2014 Category: Hematology Authors: C.T. Hackett, R.S. Ramanathan, K. Malhotra, M.R. Quigley, K.M. Kelly, M. Tian, J. Protetch, C. Wong, D.G. Wright, A.H. Tayal Tags: Regular Article Source Type: research
Cancer as a risk factor for stroke in atrial fibrillation patients receiving long-term oral anticoagulant therapy
cancer and cerebrovascular disease are among the most common causes of death in the developed countries and are both associated with a steep increase in incidence among the elderly population. Despite being a less frequent neurological complication in cancer patients, compared to metastases or neurotoxicity from anticancer treatment, stroke incidence in cancer patients is high [1]. The pathophysiology of stroke in cancer patients is largely unknown [2] and can be attributed to cardiac or non-cardiac embolism.
Source: Thrombosis Research - June 18, 2015 Category: Hematology Authors: Gentian Denas, Vittorio Pengo, Roberta Joppi, Paolo Prandoni Source Type: research
Thrombophilia testing in young patients with ischemic stroke
The possible significance of thrombophilia in ischemic stroke remains controversial. We aimed to study inherited and acquired thrombophilias as risk factors for ischemic stroke, transient ischemic attack (TIA) and amaurosis fugax in young patients.
Source: Thrombosis Research - November 7, 2015 Category: Hematology Authors: Sidse Høst Pahus, Anette Tarp Hansen, Anne-Mette Hvas Tags: Full Length Article Source Type: research
Ischemic stroke in cancer patients treated with direct oral anticoagulants for venous thromboembolism
Direct oral anticoagulants (DOACs) are at least as efficacious as conventional anticoagulation therapy for the initial and long-term treatment of cancer patients with venous thromboembolism (VTE). Whether DOACs are non-inferior to low-molecular-weight heparin for the management of cancer patients with VTE is under investigation. In addition, the efficacy of DOACs for the treatment of cancer patients with arterial thrombosis (e.g., ischemic stroke) remains unclear. Herein, we report on two cancer patients admitted to our hospital with Stage IV gastric adenocarcinoma who were being treated with DOACs due to a history of VTE ...
Source: Thrombosis Research - March 31, 2017 Category: Hematology Authors: Yasufumi Gon, Manabu Sakaguchi, Junji Takasugi, Hideki Mochizuki Tags: Letter to the Editors-in-Chief Source Type: research
Cancer, atrial fibrillation, and stroke
Cancer patients appear to be at increased risk for atrial fibrillation. Although surgery and chemotherapy exacerbate this risk, this association is observed even in the absence of any cancer-specific treatment. The underlying mechanism of this is likely multifactorial, but systemic inflammation and autonomic dysregulation are hypothesized to play critical roles. Cancer and atrial fibrillation are both independent risk factors for ischemic stroke; however, it is not clear whether this translates to an increased risk of stroke in patients with both comorbidities.
Source: Thrombosis Research - May 9, 2017 Category: Hematology Authors: Tess Sudenis, Marc Carrier, Gr égoire Le Gal Tags: Review Article Source Type: research
Ischemic stroke rates decline in patients with atrial fibrillation as anticoagulants uptake improves: A Swedish cohort study
The impact of the increased anticoagulants uptake on incidence rate of ischemic stroke is largely unknown. We assessed time trends in rates of ischemic stroke in patients with incident atrial fibrillation (AF) diagnosed between 2011 and 2013.
Source: Thrombosis Research - August 10, 2017 Category: Hematology Authors: Natalia Mochalina, Nazim Isma, Peter J. Svensson, Anders Sj älander, Maj Carlsson, Tord Juhlin, Mattias Wieloch Tags: Full Length Article Source Type: research
Predicted risk of stroke and bleeding and use of oral anticoagulants in atrial fibrillation: Danish nationwide temporal trends 2011 –2016
We used Danish nationwide registries to examine temporal trends in the predicted stroke and bleeding risks (mean CHA2DS2-VASc and HAS-BLED scores per year, respectively) as well as the combination of selected stroke and bleeding risk factors per year among atrial fibrillation (AF) patients initiated for the first time between 2011 and 2016 on vitamin K antagonists (VKAs), dabigatran, rivaroxaban, or apixaban.
Source: Thrombosis Research - October 16, 2017 Category: Hematology Authors: Alexandar Dukanovic, Laila Staerk, Emil Loldrup Fosb øl, Kasper Gadsbøll, Gunnar Hilmar Gislason, Jonas Bjerring Olesen Tags: Full Length Article Source Type: research
Red cell distribution width as a predictor of 1-year survival in ischemic stroke patients treated with intravenous thrombolysis
Red cell distribution width (RDW) has been found to be a prognostic marker in vascular diseases. Increased RDW predicted mortality and outcome after ischemic stroke however, the underlying mechanisms are unclear. Our study aimed to clarify the relation of RDW with stroke severity and 1-year survival.
Source: Thrombosis Research - February 6, 2018 Category: Hematology Authors: Jo ão Pinho, Sofia Alexandra Marques, Eduardo Freitas, José Araújo, Mariana Taveira, José Nuno Alves, Carla Ferreira Tags: Full Length Article Source Type: research
Ninety-day prognosis of patients receiving direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: The real life evidence
Patients who receive antithrombotic therapy as secondary prevention in the early phase of non valvular atrial fibrillation (NVAF)-related acute ischemic stroke (AIS) have a better prognosis compared with patients who do not receive antithrombotic treatment [1]. In the VISTA registry the incidence of stroke recurrence, symptomatic intracranial bleeding, all-cause mortality and 90-day modified Rankin Scale (mRS) ≥4 in patients with NVAF-related AIS not receiving antithrombotic treatment was 19.8%, 9.3%, 40.7% and 65.3%, respectively compared with patients receiving vitamin K antagonists (VKAs) (10.6%, 2.9%, 25.5% and 46.6%...
Source: Thrombosis Research - November 3, 2018 Category: Hematology Authors: Luca Masotti, Elisa Grifoni, Alessandro Dei, Vieri Vannucchi, Federico Moroni, Stefano Spolveri, Grazia Panigada, Giancarlo Landini Tags: Letter to the Editors-in-Chief Source Type: research
P5. Abstract Title: Characterization of Unfractionated Heparin Infusions in a Comprehensive Stroke Centre
Stroke patients with arterial or venous intraluminal thrombus (ILT) are at high risk of stroke recurrence and embolic or hemorrhagic complications. Treatment with anticoagulation remains challenging in this group of patients due to onset of action, efficacy, and risk of hemorrhage. Traditionally, unfractionated heparin (UFH) has been used due to its short half-life in the context of risk of hemorrhagic transformation of the infarct zone. Heparin nomograms and associated bolus dosing are not standardized in clinical practice across centres and patients can exhibit long epochs of time under or over the therapeutic PTT range.
Source: Thrombosis Research - September 30, 2019 Category: Hematology Authors: H. Khosravani, P. Pham, C. Shen, C. Wong Source Type: research
Extracellular vesicles in atrial fibrillation and stroke
Atrial fibrillation (AF) is associated with a 5-fold increased risk of thromboembolic stroke. Extracellular vesicles (EVs) convey pathophysiological information and are possible biomarkers for risk of stroke.
Source: Thrombosis Research - July 14, 2020 Category: Hematology Authors: Åsa Thulin, Johan Lindbäck, Christopher B. Granger, Lars Wallentin, Lars Lind, Agneta Siegbahn Tags: Full Length Article Source Type: research
Therapeutic efficacy of heparin and direct factor Xa inhibitors in cancer-associated cryptogenic ischemic stroke with venous thromboembolism
Anticoagulation therapy, especially using heparin or recently developed oral direct factor Xa inhibitors (DiXals), is recommended as first-line treatment for cancer-related venous thromboembolism (VTE). However, the preventive efficacy of these anticoagulants for cancer-associated ischemic stroke is still unknown. We retrospectively investigated the efficacy of subcutaneous unfractionated heparin (UFH) and DiXals for preventing the recurrence of cancer-associated cryptogenic ischemic stroke with VTE.
Source: Thrombosis Research - August 23, 2021 Category: Hematology Authors: Genpei Yamaura, Takeshi Ito, Yosuke Miyaji, Naohisa Ueda, Yoshiharu Nakae, Takayuki Momoo, Tatsu Nakano, Yuji Johmura, Yuichi Higashiyama, Hideto Joki, Hiroshi Doi, Hideyuki Takeuchi, Tatsuya Takahashi, Shigeru Koyano, Shigeki Yamaguchi, Mutsumi Yokoyama, Source Type: research
Association of antithrombotic medications and composition of thrombi retrieved by mechanical thrombectomy in acute ischemic stroke
Timely restoration of blood perfusion through thrombolysis and/or mechanical thrombectomy (MT) is an important step in salvaging ischemic brain in stroke patients. MT has opened an avenue for histological evaluation of thrombi and over the last couple of years our knowledge on the thromboembolus histological and mechanical properties and effects of these properties on the success of MT has grown significantly [1,2]. Two major classes of antithrombotic therapies, including antiplatelet and anticoagulant drugs, have been used for both management and prevention of stroke.
Source: Thrombosis Research - September 26, 2021 Category: Hematology Authors: Mehdi Abbasi, Oana Madalina Mereuta, Sean F. Fitzgerald, Daying Dai, Alejandro A. Rabinstein, Ramanathan Kadirvel, David F. Kallmes, Waleed Brinjikji Tags: Letter to the Editors-in-Chief Source Type: research
Age and composition of the thrombus retrieved by mechanical thrombectomy from patients with acute ischemic stroke are associated with revascularization and clinical outcomes
Understanding the composition of stroke thrombi retrieved by mechanical thrombectomy is essential to clarify the pathogenesis of stroke. However, it is difficult to evaluate thrombus composition precisely and objectively. Immunohistochemical staining was used to evaluate thrombus composition and age.
Source: Thrombosis Research - September 6, 2022 Category: Hematology Authors: Hisao Shimizu, Kinta Hatakeyama, Kozue Saito, Ryogo Shobatake, Nobuyuki Takahashi, Jun Deguchi, Hidemori Tokunaga, Keiji Shimada, Ichiro Nakagawa, Kaoru Myochin, Kazuya Sakai, Masayuki Kubo, Atsushi Yamashita, Chiho Obayashi, Kazuma Sugie, Masanori Matsum Tags: Full Length Article Source Type: research
Stroke mortality in cancer survivors: A population-based study in Japan
The association between cancer survivors and stroke deaths remains unclear. We aimed to evaluate the risk of fatal stroke in patients with cancer.
Source: Thrombosis Research - January 9, 2023 Category: Hematology Authors: Yasufumi Gon, Ling Zha, Tsutomu Sasaki, Toshitaka Morishima, Yuko Ohno, Hideki Mochizuki, Tomotaka Sobue, Isao Miyashiro Source Type: research
